US2793158A - Injection solutions containing pyridine carboxylic acid nu-hydroxymethylamides - Google Patents
Injection solutions containing pyridine carboxylic acid nu-hydroxymethylamides Download PDFInfo
- Publication number
- US2793158A US2793158A US535735A US53573555A US2793158A US 2793158 A US2793158 A US 2793158A US 535735 A US535735 A US 535735A US 53573555 A US53573555 A US 53573555A US 2793158 A US2793158 A US 2793158A
- Authority
- US
- United States
- Prior art keywords
- carboxylic acid
- pyridine carboxylic
- formaldehyde
- hydroxymethylamides
- ureide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- This invention relates to injection solutions of N-hydroxymethyl pyridine carboxylic acid amides, substantially free of formaldehyde, containing a hexoseureide in a quantity not exceeding 15% by weight, and particularly to an injection solution of N-hydroxymethyl nicotinic acid amide substantially free of formaldehyde, containing a hexoseureide in a quantity not exceeding 15% by weight, but preferably in a quantity from 8% to 15% by weight.
- hydroxymethyl amides of pyridine carboxylic acids have been introduced more and more in the medical practice. They are in particular used in the therapy of bile-duct troubles, in the chemotherapy of disbactery of the colon, and for similar purposes.
- the hydroxymethyl amides in question are usually applied perorally, however, in many cases also parenterally, and particularly intravenously.
- Aqueous solutions of pyridine carboxylic acid hydroxymethyl amides when stored for a long time, contain free formaldehyde, as an equilibrium takes place between pyridine carboxylic acid hydroxy methyl amides on one hand and pyridine carboxylic acid amides and formaldehyde on the other hand. Since, as is known, free formaldehyde, when applied intravenously, even in small concentrations, causes pain, there was a definite need for the production of aqueous solutions of pyridine carboxylic acid hydroxymethyl amides, which are free of or poor in formaldehyde.
- ureides of hydroxyaldehydes, ureides of polyhydroxyaldehydes, or ureides of polyhydroxyketones when added to aqueous solutions of hydroxy methyl pyridine carboxylic acid amides are capable to reduce the formaldehyde content of such solvents to below 1%.
- Ureides of hexoses and in particular the glucose ureide have proved especially effective.
- mice bear for instance more than 20 g./kg. glucose ureide when applied perorally or subcutaneously, and more than 10 g./ kg. when applied intravenously.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
Description
United Sttes Patent INJECTION SOLUTIGNS gARBOXYLIC ACID N HYDROXYMETHYL MIDES Carl Richter, Schalfhausen, and Alfred Willi, Herblingen, Canton Schalfhausen, Switzerland, assignors to Cilag imited, Schaifhausen, Switzerland, a Swiss company No Drawing. Application September 21, 1955, Serial No. 535,735
Claims priority, application Switzerland September 24, 1954 2 Claims. (Cl. 167-65) This invention relates to injection solutions of N-hydroxymethyl pyridine carboxylic acid amides, substantially free of formaldehyde, containing a hexoseureide in a quantity not exceeding 15% by weight, and particularly to an injection solution of N-hydroxymethyl nicotinic acid amide substantially free of formaldehyde, containing a hexoseureide in a quantity not exceeding 15% by weight, but preferably in a quantity from 8% to 15% by weight.
In the past years, hydroxymethyl amides of pyridine carboxylic acids, and especially of nicotinic acid, have been introduced more and more in the medical practice. They are in particular used in the therapy of bile-duct troubles, in the chemotherapy of disbactery of the colon, and for similar purposes. The hydroxymethyl amides in question are usually applied perorally, however, in many cases also parenterally, and particularly intravenously.
Aqueous solutions of pyridine carboxylic acid hydroxymethyl amides, when stored for a long time, contain free formaldehyde, as an equilibrium takes place between pyridine carboxylic acid hydroxy methyl amides on one hand and pyridine carboxylic acid amides and formaldehyde on the other hand. Since, as is known, free formaldehyde, when applied intravenously, even in small concentrations, causes pain, there was a definite need for the production of aqueous solutions of pyridine carboxylic acid hydroxymethyl amides, which are free of or poor in formaldehyde.
An adjustment of the equilibrium status between pyridine carboxylic acid hydroxy methyl amide on one hand and pyridine carboxylic acid amide and formaldehyde on the other hand by addition of excessive pyridine carboxylic acid amide in favor of pyridine carboxylic acid hydroxy methyl amide was taken into consideration.
Further examinations of the situations showed that, in order to reduce the formaldehyde content to below 0.1%, pyridine carboxylic acid amide would have to be added in such quantities, that these would by far exceed the physiologically permissible measure. A solution to this problem could therefore not be found in this manner alone.
The value of the constant of the equilibrium [CH O]-[pyridine carboxylic acid amide] [pyridine carboxylic acid hydroxy methyl amide] within narrow limits,-fwh'ich had to be adapted to the physiological needs, so that also here'noabsolute success could be expected. With these alterations it was possible to reduce the velocity of decomposition to such an extent that for a few years the content of pyridine carboxylic acid hydroxy methyl amide does not sink substautially, but already a small decomposition grade is enough to let the content of formaldehyde reach the tolerance limit.
As a measure promising success in hindering the building of formaldehyde there could only be seen the addition of physiologically inert formaldehyde acceptors. However, known formaldehyde acceptors, such as urea, thiourea, aminotriazines, etc. are disadvantageous insofar as in the presence of formaldehyde they polymerize easily and form products which are not soluble in water.
It was now surprisingly found that ureides of hydroxyaldehydes, ureides of polyhydroxyaldehydes, or ureides of polyhydroxyketones, when added to aqueous solutions of hydroxy methyl pyridine carboxylic acid amides are capable to reduce the formaldehyde content of such solvents to below 1%. Ureides of hexoses and in particular the glucose ureide have proved especially effective.
The following contents of free formaldehyde in 4% aqueous solutions of nicotinic acid hydroxy methyl amide with 0.01 M citrate buffer (pl-1:60) at room temperature (18 to 25 C.) were established:
(G=glucosc ureide.)
From the values of the above table can be interpolated that an addition of 8% by weight glucose ureide suflices to reduce the formaldehyde content, even after a longer storage, to below 0.1%, and extrapolated that additions of over 15% by weight glucose ureide do not yield a further substantial reduction of the formaldehyde content. This fact was confirmed by extended experiments with various additions of glucose ureide.
It has been proved that the mechanism of the formaldehyde bond consists in a hfliydroxy methylation of the ureide. The quantitative conformance of the CHzO- values in the above table with the calculated values has shown that glucose ureide reacts with formaldehyde only when the latter is already split oif from the hydroxy methyl nicotinic acid amide.
The formaldehyde accepting addition, the glucose ureide, and the hydroxy methyl glucose ureide which forms with the time, are exceptionally well soluble in water, so that the aqueous solutions never become turbid. They also show an extremely low toxicity, so that the two bodies, when used in normal dosing limits, may be considered physiologically indifferent. White mice bear for instance more than 20 g./kg. glucose ureide when applied perorally or subcutaneously, and more than 10 g./ kg. when applied intravenously.
In the same manner as described above, there may also be obtained with the aid of hexose ureides solutions of isonicotinic acid-N-hydroxymethyl amide which are practically free of formaldehyde.
What we claim is:
1. An injection solution of N-hydroxy methyl nicotinic acid amide substantially free of formaldehyde, contaim'ng glucose ureide in a quantity from 8% to 15% by References Cited in the file of this patent weight FOREIGN PATENT 2. Injection solutions of N-hydroxy methyl pyridine 809 316 F S carboxylic acid amides substantially free of formalde- 1936 hyde, containiug glucose ureide in a quantity from 8% 5 OTHER REFERENCES to 15% by weight Gehes Codex, 8th ed., p. 103, Wissenschaftlische Verlagsgesellschaft, Stuttgart.
Claims (1)
1. AN INJECTION SOLUTIN OF N-HYDROXY METHYL NICOTINIC ACID AMIDE SUBSTANTIALLY FREE OF FORMALDEHYDE, CONTAINING GLUCOSE UREIDE IN A QUANTITY FROM 8% TO 15% BY WEIGHT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2793158X | 1954-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2793158A true US2793158A (en) | 1957-05-21 |
Family
ID=4571836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US535735A Expired - Lifetime US2793158A (en) | 1954-09-24 | 1955-09-21 | Injection solutions containing pyridine carboxylic acid nu-hydroxymethylamides |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2793158A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3149033A (en) * | 1961-02-06 | 1964-09-15 | Universal Drug And Res Lab Inc | Method of administering aldohexoseurea hypoglycemic compounds to animals |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR809316A (en) * | 1935-08-30 | 1937-03-01 | Pagani & Cie | Process for the manufacture of semi-condensed, water-soluble artificial resins, specially prepared for the treatment of yarns and fabrics made of vegetable, natural and artificial fibers, and of animal fibers |
-
1955
- 1955-09-21 US US535735A patent/US2793158A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR809316A (en) * | 1935-08-30 | 1937-03-01 | Pagani & Cie | Process for the manufacture of semi-condensed, water-soluble artificial resins, specially prepared for the treatment of yarns and fabrics made of vegetable, natural and artificial fibers, and of animal fibers |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3149033A (en) * | 1961-02-06 | 1964-09-15 | Universal Drug And Res Lab Inc | Method of administering aldohexoseurea hypoglycemic compounds to animals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Preiss et al. | INTERMEDIATES IN THE SYNTHESIS OF DIPHOSPHOPYRIDINE NUCLEOTIDE FROM NICOTINIC ACID1 | |
| US2442461A (en) | Stable solutions of calcium ascorbate | |
| US2793158A (en) | Injection solutions containing pyridine carboxylic acid nu-hydroxymethylamides | |
| ES345981A1 (en) | Pyridines and poultry feedstuffs and additives thereof containing pyridines | |
| US3940483A (en) | Antibiotic compositions and method | |
| GB937723A (en) | Pyrazolo-pyrimidines and process for their manufacture | |
| Pollack et al. | Serum phosphate changes induced by injections of glucose into dogs under various conditions | |
| JP3146218B2 (en) | Eye drops | |
| US2407412A (en) | Therapeutic solutions | |
| JPS5812206B2 (en) | Stabilized cyanamide aqueous solution | |
| US3499088A (en) | Stable aqueous solutions of coenzyme q with a polyoxyethylene hydrogenated castor oil and propylene glycol and process for the manufacture thereof | |
| HU184890B (en) | Process for preparing an antimicrobial composition with increa sed staaility | |
| GB999121A (en) | Repository antimalarial compositions | |
| GB1344853A (en) | Derivative of pyridoxine alpha-ketoglutarate | |
| US2720482A (en) | Stabilized streptomycin solutions | |
| GB834972A (en) | Stabilization of photographic bleach powders containing an alkali metal ferricyanide | |
| US2611732A (en) | Compositions containing mixtures of 4-aminosalicylic acid and its basic calcium salt | |
| US3118890A (en) | Procaine orotate | |
| GB809410A (en) | Improved method for the preparation of n-methyleneglycino-nitrile | |
| GB1319303A (en) | Sugar derivatives | |
| US2183268A (en) | Therapeutic preparation | |
| GB1306523A (en) | Aminopyridines with condensed ring system | |
| GB923942A (en) | New compounds, processes for preparing them and pharmaceutical compositions containing them | |
| Bernheim et al. | Note on the effect of caffeine on ammonia and urea excretion in rabbits | |
| ES395260A1 (en) | Imidazo-4,5-b-pyridine derivatives |